SCHEMBL1555087

SCHEMBL1555087

COc1ccc2nccc(Oc3ccc(NS(=O)(=O)C4CC4)cc3F)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 12/20 0.50
▸ KIT P10721 2/20 0.50
▸ DDR2 Q16832 1/20 0.46
▸ MET P08581 5/20 0.46
▸ FGFR2 P21802 1/20 0.46
▸ KDR P35968 1/20 0.45
▸ TBKBP1 A7MCY6 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ GAK O14976 1/20 0.45
▸ RIPK2 O43353 1/20 0.45
▸ PRKAB2 O43741 1/20 0.45
▸ ERN1 O75460 1/20 0.45
▸ STK10 O94804 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ YES1 P07947 1/20 0.45
▸ LYN P07948 1/20 0.45
▸ SRC P12931 1/20 0.45
▸ FER P16591 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25679624 0.89 DDR2 (0.46) AXLKITDDR2FGFR2KDR
SCHEMBL20782711 0.88 KIT (0.64) AXLKITMETFGFR2KDR
SCHEMBL30446793 0.88 KIT (0.64) AXLKITMETFGFR2KDR
SCHEMBL1555428 0.83 AXL (0.61) AXLMETTBKBP1PLK4AURKA
SCHEMBL22407592 0.82 KIT (0.54) AXLKITDDR2METFGFR2
SCHEMBL1555395 0.81 AXL (0.69) AXLMETPLK4AURKAGAK
SCHEMBL1555090 0.81 AXL (0.63) AXLMETPLK4AURKAGAK
SCHEMBL1555576 0.80 AXL (0.62) AXLMETTBKBP1PLK4AURKA
SCHEMBL25680627 0.80 DDR2 (0.41) AXLDDR2METKDR
SCHEMBL20782714 0.80 FGFR2 (0.51) AXLKITMETFGFR2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 — — WO claimed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 — — US disclosed
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2020-09-17 — — US disclosed
WO-2019046778-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF MAVUPHARMA, INC. (US) 2019-03-07 — — WO disclosed
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 — — EP disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 — — US disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 — — US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 — — US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 — — US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 — — US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 — — US disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 — — WO disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885KIT 2794/4885DDR2 3949/4885
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885KIT 2794/4885DDR2 3949/4885
US-20200291024-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 AXL 3774/4885KIT 4057/4885DDR2 1706/4885
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 AXL 3774/4885KIT 4057/4885DDR2 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback